Q-omics provides the consensus-scored DEFB124 profile across patient tissues and cancer cell-line models. DEFB124 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DEFB124 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, DEFB124 RNA expression shows 12,253 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, BLCA, and TGCT as cancer lineages where DEFB124 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB124 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB124 survival associations across molecular data types. DEFB124 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB124 RNA expression–survival associations across cancer types. High DEFB124 expression shows unfavorable associations in KIRP, KIRC, KICH, MESO and UVM, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DEFB124 RNA expression.
This table summarizes DEFB124 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB124. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB124 shows lower tumor expression in BLCA, UCEC, KICH, BRCA, LUSC and STAD. The BLCA box plot shows higher DEFB124 RNA expression in normal versus tumor tissue (log2 FC = −0.521, t-test p < 0.001).
This table shows molecular features associated with DEFB124 in patient tissues and cancer cell lines. In patient samples, DEFB124 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB124 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
